Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 study of verinurad plus allopurinol in heart failure with preserved ejection fraction and hyperuricaemia
2019-004862-16Phase 2Completed
- Sponsor
- AstraZeneca
- Start
- Mar 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of verinurad in heart failure with preserved ejection fraction (HFpEF) and hyperuricemia (4 arms), sponsored by AstraZeneca. Primary endpoint: Change from baseline at Week 32 in peak VO2. Started Mar 2020; status: completed.
02
Drugs
verinurad
03
Conditions
heart failure with preserved ejection fraction (HFpEF)hyperuricemia
Beyond the preview
Go deeper on 2019-004862-16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-004862-16.